银屑病生物制剂治疗应答轨迹的界定
研究对3546例注册登记患者和2889例临床试验汇总患者应用潜类别混合模型,基于PASI纵向数据识别出四种全局应答轨迹类别,分别以应答时间、效应大小和复发为特征,各类别与体重指数、基线PASI及不同表现患病率相关,并在临床试验队列中验证。
要点
- 基于PASI纵向变化可识别四种不同的生物制剂应答轨迹类别。
- 各轨迹类别与体重指数、基线PASI和不同临床表现相关。
- HLA-C*06:02与注册登记识别的轨迹类别存在差异关联。
核心结论
- 基于疾病活动度随时间变化定义的亚组可能指示由不同生物学机制驱动的不同内型,有助于指导银屑病患者管理。
研究设计与样本
- 应用潜类别混合模型,从英国皮肤科医师协会生物制剂和免疫调节剂注册登记中3546例患者的纵向常规临床PASI数据识别轨迹亚组。
- 在四个临床试验汇总的2889例独立队列中验证轨迹亚组。
主要发现
- 发现四种离散的全局应答轨迹类别,各以应答时间、效应大小和复发为特征。
- 各轨迹类别与不同临床特征相关,如体重指数、基线PASI和不同表现的患病率。
- 在临床试验参与者第二队列中验证了生物制剂治疗启动后相似的轨迹。
- 发现遗传标记HLA-C*06:02与注册登记识别的轨迹之间存在差异关联。
临床怎么用
- 基于PASI纵向变化识别的应答轨迹亚组可能有助于指导银屑病患者的生物制剂管理。
局限性
- 未来工作旨在通过额外的分子和药理学数据广泛表征亚组,以进一步阐明这些机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effectiveness and cost-effectiveness of biologic therapies for psoriasis are significantly compromised by variable treatment responses. Thus, more precise management of psoriasis is needed. OBJECTIVES: To identify subgroups of patients with psoriasis treated with biologic therapies, based on changes in their disease activity over time, that may better inform patient management. METHODS: We applied latent class mixed modelling to identify trajectory-based patient subgroups from longitudinal, routine clinical data on disease severity, as measured by the Psoriasis Area and Severity Index (PASI), from 3546 patients in the British Association of Dermatologists Biologics and Immunomodulators Register, as well as in an independent cohort of 2889 patients pooled across four clinical trials. RESULTS: We discovered four discrete classes of global response trajectories, each characterized in terms of time to response, size of effect and relapse. Each class was associated with differing clinical characteristics, e.g. body mass index, baseline PASI and prevalence of different manifestations. The results were verified in a second cohort of clinical trial participants, where similar trajectories following the initiation of biologic therapy were identified. Further, we found differential associations of the genetic marker HLA-C*06:02 between our registry-identified trajectories. CONCLUSIONS: These subgroups, defined by change in disease over time, may be indicative of distinct endotypes driven by different biological mechanisms and may help inform the management of patients with psoriasis. Future work will aim to further delineate these mechanisms by extensively characterizing the subgroups with additional molecular and pharmacological data.
引用
- Geifman N, Azadbakht N, Zeng J, et al. Defining trajectories of response in patients with psoriasis treated with biologic therapies. Br J Dermatol. 2021. PMID: 33829489. doi:10.1111/bjd.20140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。